Tristel plc (TSNLF)
| Market Cap | 254.73M +9.5% |
| Revenue (ttm) | 67.82M +10.0% |
| Net Income | 10.59M +20.2% |
| EPS | 0.22 +19.8% |
| Shares Out | n/a |
| PE Ratio | 24.76 |
| Forward PE | 21.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 400 |
| Open | 6.00 |
| Previous Close | 5.52 |
| Day's Range | 5.52 - 6.00 |
| 52-Week Range | 5.00 - 6.00 |
| Beta | 0.35 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 19, 2026 |
About Tristel
Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom, Australia, Germany, Western Europe, and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers device decontamination products, including wipes system, ULT, OPH, Stella system, fuse for Stella, rinse assure, clean, EVE, medistel, EVA system, daisygrip, fuse for surfaces, dosing system, airstel, enzystel, DOK, pre-clean wipes, rinse wip... [Read more]
Financial Performance
In fiscal year 2026, Tristel's revenue was 51.12 million, an increase of 10.02% compared to the previous year's 46.46 million. Earnings were 7.98 million, an increase of 20.24%.
Financial numbers in GBP Financial StatementsNews
Tristel Annual report: H2 2026
Tristel has published its H2 2026 annual report on October 19, 2026.
Tristel Slides: H2 2026
Tristel has posted slides in relation to its H2 2026 quarterly earnings report, which was published on October 19, 2026.
Tristel Annual report: H2 2026
Tristel has published its H2 2026 annual report on October 19, 2026.
Tristel downgraded to Hold from Buy at Panmure Liberum
Panmure Liberum downgraded Tristel (TSNLF) to Hold from Buy with a 420 GBp price target
Tristel Earnings release: Trading update
Tristel released its earnings on July 22, 2026, summarizing the period's financial results.
Tristel Earnings Call Transcript: H1 2026
Record interim revenue and profit growth driven by strong UK, European, and U.S. performance, with robust cash generation and continued investment in commercial expansion. U.S. market momentum accelerates, supported by clinical guideline endorsements and strategic partnerships.
Tristel Quarterly report: H1 2026
Tristel has published its H1 2026 quarterly earnings report on March 2, 2026.
Tristel Slides: H1 2026
Tristel has posted slides in relation to its H1 2026 quarterly earnings report, which was published on March 2, 2026.